Informations générales (source: ClinicalTrials.gov)
Longitudinal, Prospective, French, Multicenter Cohort Study on Pancreatic Radiofrequency (RAFPAN2)
Observational
GCS Ramsay Santé pour l'Enseignement et la Recherche (Voir sur ClinicalTrials)
juin 2023
mai 2030
01 avril 2025
The purpose of the study is to evaluate the oncological efficacy of pancreatic
radiofrequency by the objective response rate (complete and partial responses according
to RECIST 1.1.), 5 years after the end of treatment.
Etablissements
| Les établissements d'Île-de-France ayant mis à jour leurs données Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Hichem BELKHODJA | 15/02/2024 15:48:56 | Contacter | ||
| Les établissements sans correspondance certaine dans le répertoire FINESS dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
| CHI Toulon La Seyne - 83056 - Toulon - France | Philippe AH-SOUNE, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Age ≥ 18 years old;
- Patient to be treated for a pancreatic tumor by ultrasound-guided RF with a fine
needle;
- Indication of pancreatic radiofrequency validated in a Multidisciplinary
Consultation Meeting;
- Patient able to understand the information related to the study;
- Patient accepting study follow-up visits;
- Patient having been informed and agreeing to participate in the study.
- Age ≥ 18 years old;
- Patient to be treated for a pancreatic tumor by ultrasound-guided RF with a fine
needle;
- Indication of pancreatic radiofrequency validated in a Multidisciplinary
Consultation Meeting;
- Patient able to understand the information related to the study;
- Patient accepting study follow-up visits;
- Patient having been informed and agreeing to participate in the study.
- Patient with a contraindication to radiofrequency treatment;
- Pregnant or breastfeeding women